NASDAQ:GALT Galectin Therapeutics Q3 2025 Earnings Report $3.90 +0.14 (+3.72%) As of 10/2/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Galectin Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS -$0.11Beat/MissMissed by -$0.02One Year Ago EPSN/AGalectin Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGalectin Therapeutics Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time8:00AM ETUpcoming EarningsGalectin Therapeutics' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Galectin Therapeutics Earnings HeadlinesGalectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comGalectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. UihleinAugust 4, 2026 | quiverquant.comQGalectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance SheetAugust 4, 2026 | globenewswire.comGalectin Therapeutics Insider Trading Activity | NASDAQ:GALT | BenzingaJuly 14, 2026 | benzinga.comSee More Galectin Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email. Email Address About Galectin TherapeuticsGalectin Therapeutics (NASDAQ:GALT) is a clinical-stage biopharmaceutical company focused on developing therapies that target galectin-3, a protein associated with fibrosis, inflammation and immune-system regulation. The company’s research is aimed at addressing serious diseases for which treatment options remain limited. Its lead product candidate is belapectin, an investigational galectin-3 inhibitor designed to reduce fibrotic activity and potentially improve liver-related complications. Galectin Therapeutics has primarily evaluated belapectin in patients with metabolic dysfunction-associated steatohepatotic cirrhosis, formerly referred to as nonalcoholic steatohepatitis cirrhosis, including complications such as portal hypertension and esophageal varices. Galectin Therapeutics conducts its development activities through clinical research and collaborations in the United States and other relevant markets. As an investigational-stage company, its products remain subject to clinical testing and regulatory review and are not broadly approved as commercial treatments. The company is headquartered in Norcross, Georgia.View Galectin Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
